The Commonwealth Serum Laboratories was established in Australia in 1916 to service the health needs of a nation isolated by war. Over the ensuing years CSL provided Australians with rapid access to 20th century medical advances including insulin and penicillin, and vaccines against influenza, polio and other infectious diseases. CSL Limited was incorporated in 1991 and listed on the Australian Securities Exchange (ASX) in 1994.
Since then, CSL has acquired a number of companies. They include: Aventis Behring, which is now known as global biotechnology leader CSL Behring; U.S. plasma collector Nabi, which helped to form the world's premier plasma collection company in CSL Plasma; the Novartis influenza vaccine business, now integrated and known as Seqirus, one of the largest influenza vaccine providers in the world; Calimmune, a leader in gene-modification and cell delivery technology; and Vitaeris, a biopharmaceutical company focused on the development of clazakizumab as a potential treatment option for organ transplant recipients experiencing rejection. Their combined and rich histories make CSL the innovative global leader it is today.
"Vita" means life. At CSL Behring, our focus is on developing and delivering biotherapies that save lives. Vita is the place where we share those stories, to provide insight about, and awareness of, the ever-evolving promise of biotechnology.
Vita’s audience includes patients and their families, health care providers, the media, our people and other key stakeholders. Our content is rooted in great storytelling: well-told narratives; clear, explanatory prose; and compelling photos, video and infographics. You can find these stories on the Vita section of our website; direct to your inbox through our weekly newsletter; and on social media.
Precious Raw Material: Plasma
A subsidiary of CSL Behring, CSL Plasma operates one of the world's largest and most sophisticated plasma collection networks, with more than 300 plasma collection centers in the U.S., Europe and China.Visit CSL Plasma